Immuno-Oncology | Specialty

Dr. Topalian on the PD-1 Immunotherapy BMS-936558

June 22nd 2012

Dr. Suzanne Topalian, from the Johns Hopkins University School of Medicine, on the PD-1 Targeted Immunotherapy BMS-936558.

Another Bite of the Immunotherapy Apple

June 22nd 2012

In the past few years the pace of discovery of effective immunotherapies has accelerated as a consequence of better chemistry and understanding of immune biology.

Kathleen Madden on the Importance of Patient Education

June 21st 2012

Kathleen Madden, from NYU Langone Medical Center, on the Importance Educating Patients About Ipilimumab's Side Effects.

Dr. Ryan Discusses Sequencing Prostate Cancer Therapies

June 18th 2012

Dr. Charles Ryan, from UCSF Helen Diller Family Comprehensive Cancer Center, Discusses Sequencing Castration-Resistant Prostate Cancer Therapies.

Four Later-Stage Immunotherapy Strategies Appear Promising

June 14th 2012

While many approaches to using immunotherapy for the treatment of prostate cancer are under study, four strategies currently in later-stage clinical development have emerged as the most promising.

Dr. Brahmer on the PD-1 Immunotherapy BMS-936558

June 7th 2012

Dr. Julie Brahmer, from the Sidney Kimmel Comprehensive Cancer Center, on the PD-1 Immunotherapy BMS-93655 Clinical Trial

PD-1 Immunotherapy Makes Strong Showing in Three Tumor Types

June 2nd 2012

An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.

Dr. Concepcion Discusses Prostate Cancer Therapies

May 31st 2012

Dr. Raoul Concepcion, from Urology Associates, PC, Nashville, TN, Discusses New Prostate Cancer Therapies.

Krista Rubin on Understanding Ipilimumab's Toxicities

May 24th 2012

Krista Rubin, from Massachusetts General Hospital Cancer Center, on Understanding Ipilimumab's Toxicities.

Ipilimumab Demonstrates Activity in Patients With Brain Metastases

May 22nd 2012

Ipilimumab generates antitumor activity in some patients with advanced melanoma whose disease has metastasized to the brain without resulting in unexpected toxicities.

Dr. Gomella Discusses the IMPACT Trial Survival Benefit

May 21st 2012

Dr. Leonard Gomella, from the Jefferson Kimmel Cancer Center, on the Provenge IMPACT Trial Survival Benefit

Sipuleucel-T Stimulates Response in Localized Setting, Study Finds

May 11th 2012

The neoadjuvant administration of sipuleucel-T may stimulate an immune response in patients with localized prostate cancer without adversely affecting their surgeries.

Metastatic Melanoma: Timely Approval of Yervoy

May 9th 2012

After a long fight with melanoma, the Roman Catholic parish priest Father Arthur Humphrey was able to receive the immunotherapeutic agent Yervoy, which greatly improved his prognosis.

Krista Rubin on Managing Ipilimumab-related Dermatitis

May 6th 2012

Krista Rubin, MS, RN, FNP-BC, from Massachusetts General Hospital Cancer Center, on Managing Ipilimumab-related Dermatitis.

Talking to Prostate Cancer Patients About Sipuleucel-T: Nurses Assure Smooth Sailing During Treatment

May 4th 2012

Nurses play vital roles in assuring that patients with metastatic castration-resistant prostate cancer (mCRPC) are optimally treated with sipuleucel-T.

Dr. Sartor on Combining Radium-223 and Provenge

April 25th 2012

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses a New Trial Combining Radium-223 and Provenge

Dr. Gomella Suggests Provenge Benefit Understated

April 20th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Examines the Understating of Provenge Benefits

Revised View Enhances Provenge OS Data

April 19th 2012

A further analysis of clinical trial data for sipuleucel-T suggests that it may have delivered a greater OS benefit than previously described.

Dr. Gomella on the Cost of the Immunotherapy Sipuleucel-T

March 1st 2012

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on the Cost of the Immunotherapy Sipuleucel-T

Dr. Alter Discusses Provenge MOA and Tolerability

December 2nd 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses Provenge MOA and Tolerability